SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 13, 2018--
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing innovative
immuno-oncology protein therapeutics, today announced that Marc Belsky,
Senior Vice President and Chief Financial Officer, has resigned to
pursue another opportunity. Mr. Belsky will continue in his current role
until April 6, 2018. Five Prime plans to undertake a search for a new
Chief Financial Officer promptly.
“We thank Marc for his important contributions to Five Prime, including
building our finance and accounting organization and leading the company
through its initial public offering in 2013, as well as additional
follow-on public offerings,” said Aron Knickerbocker, Chief Executive
Officer of Five Prime Therapeutics. “Marc’s leadership has contributed
significantly to Five Prime’s financial strength, and we wish him much
success in his future endeavors.”
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and late preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn,
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking statements
are based on Five Prime's expectations and assumptions as of the date of
this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results to
differ from those expressed or implied in the forward-looking statements
in this press release are discussed in Five Prime's filings with the
U.S. Securities and Exchange Commission, including the "Risk Factors"
contained therein. Except as required by law, Five Prime assumes no
obligation to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
View source version on businesswire.com: http://www.businesswire.com/news/home/20180313006443/en/
Source: Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Heather Rowe, 415-365-5737